Welcome, Guest. Please login or register.
May 26, 2024, 11:19:26 am

Login with username, password and session length

  • Total Members: 6309
  • Latest: Vicki
  • Total Posts: 55126
  • Total Topics: 4851
  • Online Today: 98
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 39
Total: 39


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Addiction Specialists Identify Barriers to Treating Hepatitis C  (Read 5682 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Addiction Specialists Identify Barriers to Treating Hepatitis C
« on: December 04, 2017, 10:38:27 am »
According to clinicians who care for those taking opioid agonist therapy (OAT) for addiction to drugs such as heroin and prescription painkillers, there are numerous barriers to treating hepatitis C virus (HCV) among this population. The hope is that by identifying and ultimately modifying such barriers, clinicians will be able to help reduce the high burden of hep C among people who inject drugs (PWID).

Researchers from the C-SCOPE study conducted a cross-sectional survey of 203 health care providers practicing at clinics that provide OAT in the United States (82 clinicians), Canada (16), Europe (92) and Australia (13).



© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.